Here are five notes:
1. By 2024, the market is expected to reach $9.8 billion.
2. More adoption of grafts and organ substitutes for reconstructive surgeries is spurring market growth.
3. However, difficulty finding a material that can adapt to a surrounding environment’s biology poses as a barrier to market expansion.
4. Last year, xenografts held a more than 50 percent market share.
5. In 2015, North America dominated the market with a revenue share surpassing 50 percent. The Asia-Pacific region, however, is likely to have the fastest growth due to its target population and improving healthcare infrastructure.
More articles on devices:
Analysts give Mazor Robotics average price target of $27.67 — 5 insights
Kyocera Medical receives FDA clearance for total hip system: 4 takeaways
Aurora Spine develops mobile app to offer product information: 4 quick points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
